MSLN and cancer: In another study, Cerise et al. focused on developing anti-Mesothelin (MSLN) recombinant immunotoxins (RITs) for colorectal cancer (CRC), as well as other cancers expressing MSLN, such as pancreatic, ovarian, and mesothelioma tumors.